Overview

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Phase:
PHASE3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
retatrutide
Tirzepatide